The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
AbbVie gets a cMet niche
Emrelis becomes the first drug for cMet-positive NSCLC, but only for the highest expressers.
Another TIGIT bites the dust
GSK and iTeos dump belrestotug, with the latter now looking at “strategic alternatives”.
Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Unharmonious ivonescimab reveal for Summit
The same trial that sent Summit up 272% sees the stock crash 36%.
AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
